1/25/2013

A stock offering by Trius Therapeutics is bringing in $34.1 million to fund research and development and other corporate expenses. Tedizolid phosphate, the firm's lead product, is being tested against severe infections such as methicillin-resistant Staphylococcus aureus.

Related Summaries